Eli Lilly Partners With China's InnoCare on Up to $3.35 Billion Drug Deal
The US pharmaceutical giant will pay a $100 million upfront fee to collaborate with the Beijing-based biotech firm on five undisclosed drug targets.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story
Price data
| Time | Chance of yes |
|---|---|
| now | 12% |
| 27 Sept, 18:13 UTC | 12% |
| 27 Sept, 11:33 UTC | 15% |
| 27 Sept, 04:45 UTC | 14% |
| 26 Sept, 16:48 UTC | 12% |
| 26 Sept, 15:48 UTC | 15% |
| 24 Sept, 05:29 UTC | 7% |
Replay the odds, article by article
Step through each article in the order it published and watch Eli Lilly respond.
The story so far
2 publishers have covered this in 3 articles since 24 Sept 2026. Quartz published first, on 24 September at 17:20 UTC; South China Morning Post followed 31h 40m later. The most recent article, from South China Morning Post, appeared on 26 September at 01:00 UTC.
Outlets reporting it: Quartz, South China Morning Post.
One prediction market prices this story:
- Eli Lilly — the market puts it at 12%, with $103 traded in the last 24 hours, closing 1 Jan 2027. The outcome is Yes if the U.S. federal government takes any financial stake in Eli Lilly before January 1, 2027. Otherwise, the outcome is No. Readers often mistake the linked news story about Novo Nordisk for a relevant event, but only actions by the U.S. federal government regarding Eli Lilly count.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
How it unfolded
Every source in the order it published, with the odds on Eli Lilly at that moment. A dash means the source published before we started tracking prices.
- QuartzEli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion7%
- QuartzEli Lilly kooperiert mit Chinas InnoCare bei einem Medikamentenabkommen im Wert von bis zu 3,35 Milliarden US-Dollar.7%
- South China Morning PostChina’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts7%
- Current odds12%
Sources
Every article we clustered into this story. Headlines link to the publisher.
- China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts South China Morning Post
- Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion Quartz
- Eli Lilly kooperiert mit Chinas InnoCare bei einem Medikamentenabkommen im Wert von bis zu 3,35 Milliarden US-Dollar. Quartz
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi Eli Lilly 12%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- Eli Lilly
- InnoCare Pharma